Nurix Therapeutics, Inc. announced that collaboration partner Sanofi S.A. had notified the Company of its decision to discontinue the Phase 1 first-in-human…
Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 3, 2026, Nurix Therapeutics, Inc. (the “ Company ”) announced that collaboration partner Sanofi S.A. (“ Sanofi ”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degr
How this was made
The 30-second read
Why it matters
The loss eliminates expected milestone and royalty payments, likely depressing NRIX's share price and raising questions about its pipeline funding.
Market read
First disclosure of a partnership termination that removes future revenue streams for a small‑cap biotech, creating immediate trading relevance.
What to watch
Potential for NRIX to re‑partner the program with another partner or pivot resources to other pipelines.
Background
Nurix Therapeutics disclosed via an SEC Form 8‑K that its partner Sanofi ended a Phase 1 trial of an oral STAT6 degrader, terminating the SAR448272 program.
Ticker impact
Sanofi discontinued the Phase 1 trial of SAR448272, ending the collaboration program and removing future milestone payments for Nurix Therapeutics.
likely downward pressure as the market prices in the loss of milestone payments
The 8‑K filing is the first public disclosure of the trial termination; such loss of revenue streams is material for a biotech of NRIX's size.
Market effects
May raise concerns for other biotech firms partnered with large pharma on early‑stage programs.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If Sanofi retains other licensed programs, NRIX could still capture future upside from remaining collaborations.
Key entities
- companyNurix Therapeutics, Inc.
Biotech company developing protein degradation therapies (ticker NRIX).
- companySanofi S.A.
Pharmaceutical partner that terminated the SAR448272 program.
